PML with dimethyl fumarate—No role for natalizumab?

Abstract

Get full access to this article

View all access options for this article.

References

Diebold

Altersberger

Decard

et al. A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence. Mult Scler 2019; 25: 1682–1685.

Berger

Koralnik

IJ.

Progressive multifocal leukoencephalopathy and natalizumab—unforeseen consequences. N Engl J Med 2005; 353(4): 414–416.

Plavina

Muralidharan

Kuesters

et al. Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. Neurology 2017; 89(15): 1584–1593.

Major

Yousry

Clifford

DB.

Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: A decade of lessons learned. Lancet Neurol 2018; 17(5): 467–480.

Frohman

Monaco

Remington

et al. JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab. JAMA Neurol 2014; 71(5): 596–602.

Marshall

Ferenczy

Daley

et al. Lymphocyte gene expression and JC virus noncoding control region sequences are linked with the risk of progressive multifocal leukoencephalopathy. J Virol 2014; 88(9): 5177–5183.

Meira

Sievers

Hoffmann

et al. Natalizumab-induced POU2AF1/Spi-B upregulation: A possible route for PML development. Neurol Neuroimmunol Neuroinflamm 2016; 3(3): e223.

Uleri

Ibba

Piu

et al. JC polyomavirus expression and bell-shaped regulation of its SF2/ASF suppressor during the follow-up of multiple sclerosis patients treated with natalizumab. J Neurovirol 2017; 23(2): 226–238.